Text Size

Characterizing PAI-1 Modulation on Monocyte Adhesion

This study has been terminated.
(Investigator left institution)
Sponsor:
Information provided by:
Vanderbilt University
ClinicalTrials.gov Identifier:
NCT00512031
First received: August 3, 2007
Last updated: July 15, 2011
Last verified: July 2011
History of Changes
  Purpose

To determine how altering the expression of a gene known as PAI-1 may affect the adhesive capacity of cells that play a critical role in the developement of human atherosclerosis.


Condition
Atherosclerosis

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Characterizing the Effects of PAI-1 Modulation on Human Monocyte Function - The Effect of PAI-1 Post-transcriptional Regulation on Human Monocyte Adhesion

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Vanderbilt University:

Estimated Enrollment: 50
Study Start Date: January 2007
Study Completion Date: July 2011
Primary Completion Date: July 2011 (Final data collection date for primary outcome measure)
Detailed Description:

The principal aim of this study is to determine if molecular regulation of the human gene PAI-1 alters the migratory properties of human myeloid and endothelial cells sufficiently enough to regulate entry and exit from the vascular space. Human monocyte become the key cellular orchestrators of human atherosclerotic plaque. We believe that a "loss" of PAI-1 activity may promote a pro-atherogenic effect in human vasculature thereby defining a novel atheroprotective effect for PAI-1 when expressed at normal levels in humans. By using RNA interference to achieve PAI-1 gene, we hope to elucidate the mechanistic basis of how PAI-1 regulation may affect human migration within the vasculature.

  Eligibility

Ages Eligible for Study:   18 Years to 50 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

Healthy volunteers

Criteria

Inclusion Criteria:

  • Ages 18-50
  • No current or past medical problems

Exclusion Criteria:

  • Patients taking prescription drugs (hormonal birth control or herbal supplements may be taken)
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00512031

Locations
United States, Tennessee
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37232-6300
Sponsors and Collaborators
Vanderbilt University
Investigators
Principal Investigator: Mohan Sathyamoorthy, MD Vanderbilt University
  More Information

No publications provided

Responsible Party: Mohan Sathyamoorthy, Vanderbilt University
ClinicalTrials.gov Identifier: NCT00512031     History of Changes
Other Study ID Numbers: 070079
Study First Received: August 3, 2007
Last Updated: July 15, 2011
Health Authority: United States: Institutional Review Board

Keywords provided by Vanderbilt University:
atherosclerosis
metabolic pathways
monocyte adhesion,

Additional relevant MeSH terms:
Tissue Adhesions
Atherosclerosis
Cicatrix
Fibrosis
Pathologic Processes
 Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases

ClinicalTrials.gov processed this record on June 17, 2013